Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

This ischemic benefit of sotagliflozin on both MI and stroke has not been observed in trials of selective SGLT2 inhibitors ... support SGLT1 inhibition as a potential mechanism for the ischemic ...

SGLT2 inhibitors represent “the hugest advance ... The various drugs “work through different mechanisms,” said Neil Skolnik, MD, professor of family and community medicine at the Sidney ...

The best-selling author and podcaster on how to preserve robust physical, cognitive and emotional health, and how Medicine ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...

Several mechanisms may be involved in this potential ... who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December ...

although with different mechanisms of action there is potential for combination use. With two large-scale trials showing a mortality benefit in hand, it looks assured that SGLT2 inhibitors will ...